Oncology Institute (NASDAQ:STLN) Stock Price Target Lowered at Lake Street Capital

Oncology Institute (NASDAQ:STLN) had its price objective reduced by investment analysts at Lake Street Capital from $10.00 to $8.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital‘s target price points to a potential upside of 120.99% from the stock’s current price.

Several other brokerages have also issued reports on STLN. Needham & Company LLC lifted their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. BTIG Research increased their price objective on shares of Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Tuesday, November 3rd. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $10.00 target price (down from $11.00) on shares of Oncology Institute in a research report on Friday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oncology Institute currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.25.

Oncology Institute Price Performance

STLN opened at $3.62 on Friday. The firm has a market cap of $357.80 million, a P/E ratio of -12.48 and a beta of 0.44. The firm has a 50-day moving average price of $6.43. Oncology Institute has a 1 year low of $2.32 and a 1 year high of $7.13.

Oncology Institute (NASDAQ:STLN) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $169.77 million during the quarter. Research analysts expect that Oncology Institute will post -0.21 EPS for the current year.

Insider Buying and Selling at Oncology Institute

In related news, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the acquisition, the insider owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. The trade was a 0.11% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 4.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc bought a new position in shares of Oncology Institute during the 2nd quarter worth approximately $41,000. AMG National Trust Bank bought a new stake in Oncology Institute in the 2nd quarter valued at $54,000. Engineers Gate Manager LP bought a new stake in Oncology Institute in the 2nd quarter valued at $67,000. Royal Bank of Canada lifted its holdings in Oncology Institute by 335.9% during the 1st quarter. Royal Bank of Canada now owns 22,257 shares of the company’s stock valued at $68,000 after purchasing an additional 17,151 shares during the last quarter. Finally, Fermata Advisors LLC acquired a new stake in Oncology Institute during the 2nd quarter valued at $70,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.